Effect of poloxamer 188 on collateral blood flow, myocardial infarct size, and left ventricular function in a canine model of prolonged (3-hour) coronary occlusion and reperfusion

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 3, 1998, Pages 239-247

  Kelly, Russel F ^a   Hursey, Tony L ^a   Patel, Roshni B ^a   Parrillo, Joseph E ^a   Schaer, Gary L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Collateral blood flow; Myocardial infarction; Poloxamer 188; Reperfusion injury

Indexed keywords

POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORONARY REPERFUSION; DOG; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BLOOD FLOW; HISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031778564     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008848026759     Document Type: Article

References (37)

1. Carter C, Fisher TC, Hamai H, et al. Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). Clin Hemorheol 1992;12:109-120.
2. Hunter RL, Papadea C, Gallagher CJ, Finlayson DC, Check IJ. Increased whole blood viscosity during coronary artery bypass surgery: Studies to evaluate the effects of soluble fibrin and poloxamer 188. Thromb Haemostas 1990;63:6-12.
3. Grover FL, Kahn RS, Heron MW, Paton BC. A nonionic surfactant and blood viscosity: Experimental observations. Arch Surg 1973;106:307-310.
4. Gaehtgens P, Benner KU. Disaggregation of human red blood cells by various surface-active agents as related to changes of cell shape and hemolysis. Acta Haematol 1975;53:82-89.
5. Smith CM, Hebbel RP, Tukey DP, Clawson CC, White JG, Vercellotti GM. Pluronic F-68 reduces the endothelial adherance and improves the rheology of liganded sickle erythrocytes. Blood 1987;69:1631-1636.
6. Schaer GL, Hursey TL, Abrahams SL, et al. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188, N.F.), a hemorheological agent that alters neutrophil function. Circulation 1994;90:2964-2975.
7. Schaer GL, Moy JN, Hursey TL, Rajwani KS, Thota V, Parrillo JE. Neutrophil function is altered by RheothRx injection (poloxamer 188), a hemorheologic agent shown to reduce reperfusion injury (abstr). J Am Coll Cardiol 1994;23:198.
8. Justicz AG, Farnsworth WV, Soberman MS, et al. Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. Am Heart J 1991;122:671-680.
9. Schaer GL, Spaccavento LJ, Browne KF, et al. Beneficial effects of RheothRx Injection in patients receiving thrombolytic therapy for aute myocardial infarction. Circulation 1996;94:298-307.
10. O'Keefe JH Jr., Grines CL, DeWood MA, et al. Poloxamer188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;78:747-750.
11. Weaver WD. Randomized, placebo controlled trial of RheothRx (poloxamer 188) injection in patients with suspected acute myocardial infarction (AMI) (abstr). Circulation 1995;92:I24.
12. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192-201.
13. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-1885.
14. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-2537.
15. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21:537-545.
16. Carr ME Jr., Powers PL, Jones MR. Effects of poloxamer 188 on the assembly, structure, and dissolution of fibrin clots. Thromb Haemost 1991;66:565-568.
17. Hunter RL, Bennett B, Check IJ. The effect of poloxamer 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinase. Fibrinolysis 1990;4:117-123.
18. Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting ischemic myocardium: Results of the NHLBI cooperative study. Circ Res 1985;56:651-665.
19. Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Circulation 1991;83:739-746.
20. Lesnefsky EJ, Van Benthuysen KM, McMurtry IF, Shikes RH, Johnston RB Jr., Horwitz LD. Lidocaine reduces canine infarct size and decreases release of a lipid peroxidation product. J Cardiovasc Pharmacol 1989;13:895-901.
21. Sandler H, Dodge HT. The use of single plane angiocardiograms for the calculation of left ventricular volume in man. Am Heart J 1968;75:325-334.
22. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Hok-Wai W Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation 1986;74:293-305.
23. Hale SL, Alker KJ, Kloner RA. Evaluation of nonradioactive, colored microspheres for measurement of regional myocardial blood flow in dogs. Circulation 1988;78:428-434.
24. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;78:760-770.
25. Romson JL, Bush LR, Jolly SR, Lucchesi BR. Cardioprotective effects of ibuprofen in experimental regional and global myocardial ischemia. J Cardiovasc Pharmacol 1982;4: 187-196.
26. Schaer GL, Karas SP, Santoian EC, Gold C, Visner MS, Virmani R. Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction. J Am Coll Cardiol 1990;15:1385-1393.
27. Vivaldi MT, Kloner RA, Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 1985;121:522-530.
28. Robinson KA, Hunter RL, Stack JE, Hearn JA, Apkarian RP, Roubin GS. Inhibition of coronary arterial thrombosis in swine by infusion of poloxamer 188. J Invas Cardiol 1990;2:9-20.
29. Carr ME Jr., Zeker SL, Jones MR. Effects of RheothRx on clot formation in platelet rich plasma (abstr). Blood 1990;76(Suppl. 1):415a.
30. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-1508.
31. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
32. Shen YT, Knight DR, Canfield DR, Vatner SF, Thomas JX Jr. Progressive change in collateral blood flow after coronary occlusion in conscious dogs. Am J Physiol 1989;256: H478-H485.
33. Schwartz H, Leiboff RH, Bren GB, et al. Temporal evolution of the human coronary collateral circulation after myocardial infarction. J Am Coll Cardiol 1984;4:1088-1093.
34. Rentrop KP, Feit F, Sherman W, Thornton JC. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University reperfusion trial. Circulation 1989;80:1166-1175.
35. Gallagher KP, Buda AJ, Pace D, Gerren RA, Shlafer M. Failure of superoxide dismutase and catalase to alter size of infarction in conscious dogs after 3 hours of occlusion followed by reperfusion. Circulation 1986;73:1065-1076.
36. Babbitt DG, Virmani R, Vildibill HD Jr., Norton ED, Forman MB. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: Effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J 1990;120:808-818.
37. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR. Reduction of myocardial infarct size by neutrophil depletion: Effect of duration of occlusion. Am Heart J 1986;112:682-690.